Posts tagged: Ondine

Ventilator Acquired Pneumonia: A Large Problem for Hospitals

Although hospitals are centers of refuge for those who need care, an unfortunate reality is that the number of people coming in and leaving these facilities inevitably results with the spread of disease and infections between patients, doctors, and other health care workers. These unintentionally transmitted diseases, born in hospital settings, are collectively known as Hospital Acquired Infections (nosocomial infections in medical literature). This class of disease results in over  99,000 deaths each year in the United States alone.

One significant form of nosocomial infection is Ventilator Acquired Pneumonia (VAP) which, as the name suggests, is pneumonia (an inflammatory condition of the lung) transmitted to patients while they are on mechanical ventilator breathing support. The incidence of this disease is between 8% and 20%, and mortality rates are between 20% and 50%. As a result, VAP has a critical impact on morbidity, length of stay, and cost of ICU care.

A significant contributor to such high rates of incidence and morbidity is the fact that patients on mechanical ventilation systems are often sedated and are rarely able to communicate or cough up the biofilm that grows in the tubes and drains down into the lungs. Typical symptoms of pneumonia may be absent or unobservable, leading to delays in detection and therefore treatment.  Under these conditions, the medical signs that a patient has acquired pneumonia are increased number of white blood cells on blood testing and new shadows (infiltrates) on chest x-rays. Other important signs are fever, low body temperature, purulent sputum, and hypoxemia (decreasing amount of oxygen in the blood).

If any of these symptoms are suspected by care takers, two conventional methods of diagnosis are deployed. The first is to collect cultures from the trachea while also scanning the chest with an x-ray to detect new or enlarging infiltrates. The other method is more invasive and involves a bronchoalveolar (where fluid is squired out small areas of the lung and recollected for examination), as well as a chest x ray.

Treatment regimens depend on the specific bacteria causing the inflammation, although a widely used first step is the prescription of empiric therapy (broad spectrum antibiotics) until the particular bacterium and its sensitivities are determined. Once the specific microorganisms implicated in generating pneumonia are known, more antibiotics are prescribed. The use of antibiotics raises the issue of resistance from the bacteria, and the related decrease of efficacy of the antibiotic in the years to come.

Photodisinfection is a non antibiotic approach under development by the research and development teams at Ondine Biomedical Inc., for the decolonization of the tubes of long term intubated patients. Pre-clinical studies have demonstrated proven effects of Photodisinfection directed toward the inner surface of the endotracheal tubes. The Exelume™ Photodisinfection system is currently being tested in NIH funded clinical trials in the US. Other Photodisinfection applications under development by Ondine include:  periodontitis, chronic sinusitis, burns & wounds, UTI, vertical transmission of HIV, nasal decolonization to reduce SSI, GI infection protection, etc.

Ondine Salutes the Dedicated Clinician and Caregiver

It takes a certain kind of person to be a great clinician and caregiver. In a world full of opportunities for education, talent and hard work, it takes a special kind of person to dedicate their lives to the pursuit of better patient outcomes.

It is a life of service, long hours, and often, lack of appreciation.

The personal sacrifice is always greater than anyone truly understands, and yet doing more for people in their hour of need is the greatest reward.

Read more »

Ondine Biomedical Inc Proudly Supports The PanAmerican PDT Association

Ondine Biomedical Inc. is a proud supporter of the mission and goals of the PanAmerican Photodynamic Therapy Association. Launched last month, the Association’s purpose is to galvanize the basic science and expertise of photodynamic therapy in the Americas. This will help encourage the study and practice of PDT in the treatment of animal and human diseases.

Many of you may not know that photodynamic therapy has been around for centuries. In fact, the earliest recorded treatment using a photosensitizing agent and a light source occurred in ancient Egypt over 3,000 years ago. Vegetable and plant substances were used as photosensitizers and sunlight was used as the light source. Patients suffering from skin diseases such as vitiligo had the photosensitizers topically applied to the damaged area, and the resulting photochemical reaction restored their tissue to a healthier state. In some cases, it even helped repigment their skin to its normal color.

Read more »

Ondine Study Shows Reduction of Endotracheal Tube Biofilm Using Photodisinfection

Ventilator-associated pneumonia is one of the most common and deadliest forms of healthcare-associated infections.  In the U.S alone, more than one million patients in healthcare facilities require mechanical ventilation every year. Up to 1 in 4 of these patients are reported to develop ventilator-associated pneumonia and up to half of them will die.1

Antimicrobial photodynamic therapy (aPDT), commonly known as Photodisinfection, is a non-invasive technique that used to study the reduction of biofilm in the lumen of an endotracheal tube. When patients undergo mechanical ventilation, an endotracheal tube is inserted into their throat to assist with breathing. This tube has long been recognized as a major factor in a patient’s risk for developing biofilm infections. For patients that require mechanical ventilation, such as those in ICUs, the biofilm can dislodge from the endotracheal tube and enter the lungs directly, often resulting in difficult-to-treat pneumonia.

Read more »

Working at Ondine: A Career Leading To A Harvard MBA

December 14, 2010 was a really special day for me. I was in my office when I got the news – I had been accepted to Harvard Business School’s MBA program. Now, as my time at Ondine comes to an end, I’ve been asked to recount my story, and how I got to the enviable position of being able to leave a job that I love for an unbelievable opportunity.

I began at Ondine in January of 2008 after returning from a backpacking trip around Western Europe. I had secured the internship the summer beforehand, and viewed it as the perfect opportunity. I had always been interested in business, but I was convinced that I would be attending dental school, having written the entrance examinations during my undergraduate degree. Ondine, having a commercially available dental product, was the hybrid I was looking for. So, armed with only my UBC degree in Cell Biology and Genetics, I set off to see what business was all about. Read more »

The Three Myths About Photodisinfection

I’ve talked before about how photodisinfection works, but I want to take a moment to clarify what I think are the three most common myths about the technology we’re working on here at Ondine.

It’s Not That New

Our products are often met with scepticism because people are unfamiliar with photodisinfection as a treatment, or even as a science.  Truth be told, photodisinfection has existed for over 100 years[i], and the research behind it has a solid foundation in the literature extending back well over 20 years.  Check out this short reference list if you don’t believe me. So why, with all this research, is photodisinfection only creeping into the marketplace now?  The simple answer is that, until Ondine, most companies have been a little hesitant to put the work in to make it a success.  Photodisinfection requires a lot from a company: an engineering team for a light source, a microbiology team for the preclinical tests, a chemistry team for the careful formulation of the photosensitizer and a regulatory team to get the product cleared for use in trials and approved clinical use.  When you add in quality control, finance, administration, and sales and marketing, you can see the inherent challenges facing a company. You can trust me that the science is there (and growing), and Ondine has proven that it has what it takes to make these products a reality.

Read more »

Ondine To Launch Ventilator-Associated Pneumonia (VAP) Photodisinfection Clinical Study

We are thrilled to announce that the FDA has approved a human clinical study to investigate the use of photodisinfection to prevent ventilator-associated pneumonia (VAP). VAP occurs when a lung infection develops in a patient ventilated with an endotracheal tube and continues to be the #1 cause of healthcare-associated infections in intensive care units. In the U.S alone, more than 1.3 million patients are mechanically ventilated every year. Of these patients, 10%-20% will develop ventilator-associated pneumonia, and up to half of them will die.

“A successful VAP study would represent a key step towards the commercialization of this new application of photodisinfection which utilizes Ondine’s patented technology and products…(our technology) has been proven to be highly effective at eliminating biofilms in ex vivo models, it is therefore ideally suited for the elimination of endotracheal tube biofilms resulting in the prevention of VAP” says Carolyn Cross, Chairman & CEO of Ondine.

Read more »

Ondine’s 100th Post – An Exciting Blogging Milestone!

Today, we celebrate our first blogging milestone – our 100th post. It’s incredible to see how far we have come, and exciting to imagine where we soon will be. You, the readers and followers of Ondine’s blogs, have played the central role in getting us here; your encouraging words, insightful comments, and guest blog posts have helped us tremendously throughout this process. Thank you so much.

Our goal has always been to make important points in bite-sized, digestible sound bites for today’s fast paced world. Our first one hundred posts have helped lay the foundation for this, and our next steps involve creating more engaging, relevant and compelling content. This will come in the form of videos, graphics, testimonials and case studies from the field.

Read more »

Ondine Chairman & CEO, Carolyn Cross, Featured In Vancouver Sun Newspaper

Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, understands too well the importance of supporting women in business.  This week, the Vancouver Sun Newspaper highlighted her involvement & support for this week’s Women Presidents’ Organization (WPO) International Conference. This is a unique event that connects highly successful women from around the world in promoting the advancement of women across all industries. The WPO is an exclusive membership organization for women presidents of multimillion-dollar companies. Collectively, members of the WPO have 24,000 years in business, generate $14 billion in annual revenues, and employ 105,000 employees.

Carolyn Cross, Chairman & CEO of Ondine Biomedical Inc, was featured in today's Vancouver Sun Newspaper

Read more »

Ondine To Participate in Vancouver General Hospital Infection Control Project

MRSAid product by Ondine Biomedical

World Health Day is celebrated on the 7th of April every year to mark the establishment of the World Health Organization (WHO). Each year, the WHO selects a key health issue and encourages people from around the world to hold events and promote actions that will improve health. It is very fitting for Ondine then that this year’s World Health Day theme is “Combating Drug Resistance.” We have spent the last 70 years using and misusing antibiotics to treat and prevent common infectious diseases. Today, we have entered an era where bacteria have developed the ability to become resistant to most antibiotics, rendering them almost useless. It is therefore imperative that non-antibiotic solutions to fight infections are developed in order to preserve the next generation of effective medicine. Read more »

Related Posts Plugin for WordPress, Blogger...

Staypressed theme by Themocracy